Jamnicki-Abegg, Marina <br/><br/>
Diabetes abolishes sildenafil-induced cGMP-dependent protein kinase-I expression and cardioprotection.  [electronic resource] 

 -  Journal of cardiovascular pharmacology  Dec 2007 
 - 670-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0160-2446 
<br/><br/><label>Standard No.: </label>10.1097/FJC.0b013e318157fd5b  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alloxan--toxicity<br/>Animals<br/>Blood Glucose--metabolism<br/>Blotting, Western<br/>Cardiotonic Agents--administration & dosage<br/>Collateral Circulation--drug effects<br/>Coronary Circulation--drug effects<br/>Cyclic GMP-Dependent Protein Kinases--metabolism<br/>Diabetes Mellitus, Experimental--blood<br/>Dogs<br/>Dose-Response Relationship, Drug<br/>Hemodynamics--drug effects<br/>Immunochemistry<br/>Injections, Intravenous<br/>Microspheres<br/>Myocardial Infarction--metabolism<br/>Phosphodiesterase 5 Inhibitors<br/>Phosphodiesterase Inhibitors--administration & dosage<br/>Piperazines--administration & dosage<br/>Purines--administration & dosage<br/>Radioisotopes<br/>Sildenafil Citrate<br/>Streptozocin--toxicity<br/>Sulfones--administration & dosage<br/>Up-Regulation